Loading...
•
Sep 30, 2022
Tyra Biosciences Q3 2022 Earnings Report
Reported financial results for the quarter ended September 30, 2022, and highlighted recent corporate progress.
Key Takeaways
Tyra Biosciences reported a net loss of $12.5 million for Q3 2022, with cash and cash equivalents totaling $263.2 million as of September 30, 2022. The company's pipeline development remains on track, including the planned initiation of the SURF301 study and the IND filing for TYRA-200 by the end of 2022.
TYRA-300 SURF301 clinical study is cleared by the FDA.
TYRA-200 IND is on track to be filed by year-end 2022.
The company continues to progress its SNÅP platform and pipeline programs.
Tyra Biosciences had cash and cash equivalents of $263.2 million as of September 30, 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...